News and Events
To Be A Scientist: How Bob Vince Changed the World
Bob Vince can't be sure where his becoming a scientist began, but where it led changed the world. As the discoverer of carbovirs, the precursor to the AIDS drug Ziagen, Vince's contribution to humanity can't be underestimated.
Though its history is one fraught with lessons and lawsuits, the drug's legacy, in the end, is and will be one of human health and some mercy for millions afflicted with HIV/AIDS.
Revenues from Ziagen has so far brought the U about $500 million, providing positions for faculty and fellowships for graduate students and postdoctoral fellows, and for the ongoing work of the center and its scientists, current and becoming, who will, like Vince, make discoveries that will continue to improve the world, through the lens of science, for years to come.
The full article by Adam Overland can be found here.
other CDD News
Fox News Highlights CDD Research: With threats of chemical war in Syria, a new antidote to poisonous cyanide attacks
Chemical weapons like anthrax, sarin, mustard and ricin often make headlines, but what about the threat of a terrorist attack unleashing cyanide? Some security experts believe the gas threat is real -- and this particular poison acts very fast, making it particularly challenging for first responders.
Fortunately, a new antidote holds promise. Research undertaken by Steven E. Patterson, Ph.D., of the University of Minnesota’s Center for Drug Design and colleagues has discovered a promising new alternative antidote. And this antidote could be self-administered, sort of like the average allergy injection pens that many small children carry with them to school. Using a simpler procedure means a far larger number of cyanide victims in a mass casualty incident could be rapidly treated. Patterson’s report appears in ACS' Journal of Medicinal Chemistry.
CDD Invention, Sulfanegen, to be Developed by Vytacera Pharma, for Anti-Cyanide Therapy
Based on research conducted at the Center for Drug Design (CDD), Sulfanegen, a treatment for cyanide poisoning, will be developed and marketed. Sulfanegen could be administered by first responders in the case of a mass casualty emergency, or to victims of smoke inhalation from a house fire.
Sulfanegen was invented by Drs. Steve Patterson; Robert Vince, director of CDD; and Herbert Nagasawa, adjunct at CDD. The research was funded by the CDD and the NIH CounterACT (Counter-measures Against Chemical Threats) program, an effort involving a number of NIH institutes that enhances the nation’s diagnostic and treatment response capabilities during a chemical emergency.
The technology was licensed exclusively to Vytacera by the university’s Office for Technology Commercialization.
November 3, 2011: Dr. Vince inducted into Minnesota Science & Technology Hall of Fame
Dr. Robert Vince, Professor and Director of the Center for Drug Design, was inducted to the Minnesota Science and Technology (MST) Hall of Fame. The MST Hall of Fame was created to honor individuals whose achievements in science have made lasting contributions to Minnesota and the world. The hall is a permanent exhibit at the Science Museum of Minnesota.
Aug 29, 2010: Dr. Vince Receives the 2010 Imbach Townsend Award
The International Society for Nucleosides, Nucleotides and Nucleic Acids has awarded Dr. Robert Vince the 2010 Imbach Townsend Award. The award is based upon Dr. Vince's fundamental contributions to nucleic acids chemistry and to science in its broadest sense. The award is sponsored by Idenix and was created to honor the founders of the International Round Table. It was given to Dr. Vince for his outstanding contributions in the chemistry of and biology of nucleoside analogues. The conference (XIX International Society for Nucleoside, Nucleotides and Nucleic Acids Meeting) was held in Lyon, France.